Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430)Trial to evaluate efficacy and safety of lerodalcibep (LIB003) and inclisiran in high risk CVD patients (LIBerate-VI) (NCT05004675)Study of efficacy and safety of lerodalcibep (LIB003) in patients with CVD on statins requiring additional LDL-C reduction (LIBerate-CVD) (NCT04797247)Study to assess the efficacy and safety of lerodalcibep (LIB003) in patients with HeFH on oral lipid therapy needing further LDL-C reduction (LIBerate-FH) (NCT04797104)Study of long term efficacy and safety of lerodalcibep (LIB003) in patients with CVD or high risk for CVD needing further LDL-C Reduction (LIBerate-HR, NCT04806893)Phase 3 study to evaluate the efficacy and safety of lerodalcibep (LIB003) with evolocumab in HoFH (NCT04034485)

PCSK9 inhibition

Do PCSK9 inhibitors increase new-onset diabetes? Another meta-analysis

A new meta-analysis involving more than 26,000 patients reports no increase in new-onset diabetes and no impact on glucose metabolism with PCSK9 inhibitor treatment. The authors performed a comprehensive medical literature to identify 18 randomized controlled studies with 26,123 patients without diabetes at study baseline….

Posted on 9 February 2018 | Posted in News

Why the 2017 ESC/EAS practical guidance on PCSK9 inhibition is needed

In the largest US analysis to date, higher LDL cholesterol levels were not associated with higher payer approval rates for PCSK9 inhibitor therapy. These data reaffirm the need for practical guidance, such as that published by a Joint Task Force from the European Society of…

Posted on 2 November 2017 | Posted in News

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters